Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Defence Therapeutics (DTCFF) Stock Price & Analysis

DTCFF Stock Chart & Stats

$0.26$0.01(3.17%)
At close: 4:00 PM EDT
$0.25$0.3$0.35$0.44 Aug17 Aug31 Aug14 Sep28 Sep12 Oct27 Oct
Day’s Range
$0.26 - $0.26
52-Week Range
$0.24 - $0.78
Previous Close
$0.25
Volume
10.41K
Average Volume (3M)
15.85K
Market Cap
$18.98M
Enterprise Value
$31.08M
Total Cash (Recent Filing)
$1.88M
Total Debt (Recent Filing)
$1.72M
Price to Earnings (P/E)
―
Beta
-0.37
Next Earnings
Nov 20, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Accum Platform And Therapeutic Pipeline

The Accum™ platform gives Defence Therapeutics a defined technological focus across immune-oncology and infectious-disease applications. If its delivery approach translates into better immune activation or treatment efficacy, it could support multiple programs and create a reusable foundation for longer-term pipeline development.

Improved Current Balance-sheet Position

Positive equity and moderate leverage in TTM 2026 provide a stronger current capital structure than the company’s earlier position. This reduces immediate balance-sheet pressure and gives the business a more stable base from which to continue research and pursue development milestones.

Free Cash Flow Loss Has Improved

Although cash flow remains negative, the smaller free cash flow loss versus prior years indicates some improvement in the pace of cash consumption. Sustaining that trend would extend the time available to advance the pipeline and could reduce the intensity of future funding requirements.

Bears Say

No Commercial Revenue

The absence of revenue confirms that Defence Therapeutics remains dependent on development progress rather than an established commercial business. Without product sales, the company has no recurring operating inflow to fund research, making future financial performance highly dependent on successful commercialization.

Widening And Volatile Net Losses

The renewed widening of net losses shows that operating costs are not yet supported by revenue and that profitability has not stabilized. Continued losses can consume capital, weaken financial flexibility, and increase the funding required before the development pipeline can produce commercial returns.

Persistent Cash Burn And Financing Dependence

Sustained negative operating and free cash flow means the company cannot currently fund operations internally. Dependence on external financing may constrain strategic flexibility and expose the development plan to dilution or capital availability risks until revenue materializes.

Defence Therapeutics News

DTCFF FAQ

What was Defence Therapeutics’s price range in the past 12 months?
Defence Therapeutics lowest stock price was $0.24 and its highest was $0.78 in the past 12 months.
What is Defence Therapeutics’s market cap?
Defence Therapeutics’s market cap is $18.98M.
When is Defence Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Defence Therapeutics’s earnings last quarter?
Defence Therapeutics released its earnings results on May 22, 2026. The company reported -$0.036 earnings per share for the quarter.
Is Defence Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Defence Therapeutics pay dividends?
Defence Therapeutics does not currently pay dividends.
What is Defence Therapeutics’s EPS estimate?
Defence Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Defence Therapeutics have?
Defence Therapeutics has 75,788,155 shares outstanding.
What happened to Defence Therapeutics’s price movement after its last earnings report?
Defence Therapeutics reported an EPS of -$0.036 in its last earnings report. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of Defence Therapeutics?
Currently, no hedge funds are holding shares in DTCFF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology